Zacks Investment Research cut shares of Vascular Biogenics Ltd (NASDAQ:VBLT) from a hold rating to a sell rating in a research note issued to investors on Saturday.

According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “

Other equities analysts have also issued reports about the stock. Roth Capital restated a buy rating and set a $17.00 price target on shares of Vascular Biogenics in a research report on Thursday, December 1st. Chardan Capital set a $20.00 price target on shares of Vascular Biogenics and gave the stock a buy rating in a research report on Tuesday, November 29th. Finally, Piper Jaffray Companies reaffirmed an overweight rating and set a $11.00 target price on shares of Vascular Biogenics in a research note on Tuesday, February 21st. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $12.90.

Shares of Vascular Biogenics (NASDAQ:VBLT) traded up 4.42% on Friday, reaching $5.43. 206,783 shares of the company traded hands. The stock’s market capitalization is $146.08 million. The company has a 50-day moving average of $5.58 and a 200-day moving average of $5.23. Vascular Biogenics has a 1-year low of $3.03 and a 1-year high of $7.58.

Vascular Biogenics (NASDAQ:VBLT) last posted its quarterly earnings results on Monday, March 27th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. Analysts anticipate that Vascular Biogenics will post ($0.66) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was posted by Marea Informative and is the sole property of of Marea Informative. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at http://www.mareainformativa.com/vascular-biogenics-ltd-vblt-bajo-a-vender-en-zacks-investment-research/108292/.

A hedge fund recently raised its stake in Vascular Biogenics stock. Menta Capital LLC boosted its position in Vascular Biogenics Ltd (NASDAQ:VBLT) by 46.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 115,735 shares of the biopharmaceutical company’s stock after buying an additional 36,482 shares during the period. Menta Capital LLC owned about 0.43% of Vascular Biogenics worth $561,000 at the end of the most recent reporting period. 14.95% of the stock is currently owned by institutional investors.

About Vascular Biogenics

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

5 Day Chart for NASDAQ:VBLT

Get a free copy of the Zacks research report on Vascular Biogenics (VBLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Vascular Biogenics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd and related stocks with our FREE daily email newsletter.